Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anastrazole (Arimidex)
Anastrazole · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Anastrazole | DRUG | - |
| Gefitinib | DRUG | - |
Inclusion Criteria: * Measurable (stage I-IIIB) non meta static non inflammatory breast cancer * Patients must post menopausal women who in the opinion of investigator would be likely to benefit from endocrine therapy. Postmenopausal patients are defined as: * Natural menopause with last menses \> ...
Top 20 of 87 competitors
Anastrazole is used for breast cancer. It is a small molecule studied in a Phase 2 neoadjuvant setting for ER+/PgR+ breast cancer, meaning it was evaluated in patients with hormone receptor positive disease before surgery. The clinical program focused on biomarker-selected patients.
Anastrazole is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the company associated with the clinical development of this small molecule in breast cancer.
Anastrazole is in Phase 2 clinical development for breast cancer. The recorded trial is a completed Phase 2 study, and the drug remains investigational rather than approved. No active trials are currently listed for this asset.
Anastrazole has been studied in one completed Phase 2 trial, NCT00255463, titled Phase II Neoadjuvant ER+/PgR+ Arimidex +/- Iressa Study. It enrolled 185 female participants across Czechia, France, Hungary, Portugal, Spain, Sweden, and the United Kingdom.
Yes, Anastrazole is also known as Arimidex. The names refer to the same drug, and the Phase 2 trial NCT00255463 uses the Arimidex name in its title. Searches for either name point to the same AstraZeneca asset.